Science

New findings from the MINDACT phase III trial – EORTC

EORTC/LinkedIn

Mar 19, 2025, 06:22

New findings from the MINDACT phase III trial – EORTC

shared a post on LinkedIn:

“Have you heard about the new findings from the MINDACT (EORTC 10041/BIG3-04) phase III trial? The findings reveal that the MammaPrint 70-gene signature can help guide chemotherapy decisions for invasive lobular carcinoma (ILC) patients.

Key findings:

16% of ILC cases are 70-gene high-risk with poor outcomes.
Survival rates by 70-gene risk are similar for ILC and NST patients.
No chemotherapy for high clinical, low genomic risk ILC patients should be considered.
MammaPrint could facilitate chemotherapy decisions for patients diagnosed with ILC.

Discover how MammaPrint could transform treatment decisions for ILC patients.

Read more.”

New findings from the MINDACT phase III trial - EORTC

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial

Authors: O. Metzger Filho, et al.

New findings from the MINDACT phase III trial - EORTC

More posts featuring EORTC.

Breast Cancer cancer chemotherapy EORTC European Organisation for Research and Treatment of Cancer fight against cancer Global awareness Global fight against cancer Invasive Lobular Carcinoma MammaPrint 70-gene MINDACT O. Metzger Filho OncoDaily Oncology

Oncologist Near Me - Douglas Flora: Pioneering AI Integration in Cancer Care

Douglas Hanahan was Honored with the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Cancer Research

Bente Mikkelsen Appointed as Director of Global Engagement Strategies at St. Jude Children's Research Hospital

Audrey Evans - mother of neuroblastoma, a force for good in the world

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer